Assessing myocardial perfusion in suspected coronary artery disease: rationale and design of the second phase 3, open-label multi-center study of flurpiridaz (F-18) injection for positron emission tomography (PET) imaging

2021 ◽  
Author(s):  
Jamieson M. Bourque ◽  
Christopher A. Hanson ◽  
Denis Agostini ◽  
Timothy M. Bateman ◽  
Jeroen J. Bax ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Suspected Coronary Artery Disease ◽  
Emission Tomography ◽  
Second Phase ◽  
Open Label ◽  
Phase 3 ◽  
Positron Emission ◽  
Artery Disease ◽  
Multi Center Study ◽  
Center Study

scholarly journals Prognostic value of regional myocardial flow reserve derived from 13N-ammonia positron emission tomography in patients with suspected coronary artery disease

2021 ◽  
Author(s):  
Elia von Felten ◽  
Dominik C. Benz ◽  
Georgios Benetos ◽  
Jessica Baehler ◽  
Dimitri Patriki ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Prognostic Value ◽  
Suspected Coronary Artery Disease ◽  
Emission Tomography ◽  
Flow Reserve ◽  
Positron Emission ◽  
Artery Disease ◽  
Myocardial Flow ◽  
Group 1

Abstract Purpose To assess the prognostic value of regional quantitative myocardial flow measures as assessed by 13N-ammonia positron emission tomography (PET) myocardial perfusion imaging (MPI) in patients with suspected coronary artery disease (CAD). Methods We retrospectively included 150 consecutive patients with suspected CAD who underwent clinically indicated 13 N-ammonia PET-MPI and who did not undergo revascularization within 90 days of PET-MPI. The presence or absence of a decreased global myocardial flow reserve (i.e., MFR < 2) as well as decreased regional MFR (i.e., ≥ 2 adjacent segments with MFR < 2) was recorded, and patients were classified as having preserved global and regional MFR (MFR group 1), preserved global but decreased regional MFR (MFR group 2), or decreased global and regional MFR (MFR group 3). We obtained follow-up regarding major adverse cardiac events (MACE, i.e., a combined endpoint including all-cause death, non-fatal myocardial infarction, and late revascularization) and all-cause death. Results Over a median follow-up of 50 months (IQR 38–103), 30 events occurred in 29 patients. Kaplan–Meier analysis showed significantly reduced event-free and overall survival in MFR groups 2 and 3 compared to MFR group 1 (log-rank: p = 0.015 and p = 0.013). In a multivariable Cox regression analysis, decreased regional MFR was an independent predictor for MACE (adjusted HR 3.44, 95% CI 1.17–10.11, p = 0.024) and all-cause death (adjusted HR 4.72, 95% CI 1.07–20.7, p = 0.04). Conclusions A decreased regional MFR as assessed by 13 N-ammonia PET-MPI confers prognostic value by identifying patients at increased risk for future adverse cardiac outcomes and all-cause death.

scholarly journals Fundamental Study of Inter-scanner Difference for a Multi-center Study in Brain Positron Emission Tomography

2012 ◽  
Vol 68 (6) ◽  
pp. 669-679
Author(s):  
Keiichi Oda ◽  
Muneyuki Sakata ◽  
Tomoyuki Nishio ◽  
Hiroyuki Tsushima ◽  
Yasuo Tanizaki ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Emission Tomography ◽  
Fundamental Study ◽  
Positron Emission ◽  
Multi Center Study ◽  
Center Study ◽  
Brain Positron Emission Tomography

scholarly journals Vulnerable plaque imaging using 18F-sodium fluoride positron emission tomography

2020 ◽  
Vol 93 (1113) ◽  
pp. 20190797 ◽  
Author(s):  
Jacek Kwiecinski ◽  
Piotr J Slomka ◽  
Marc R Dweck ◽  
David E Newby ◽  
Daniel S Berman
Keyword(s):  
Coronary Artery Disease ◽  
Positron Emission Tomography ◽  
Coronary Artery ◽  
Sodium Fluoride ◽  
Imaging Modality ◽  
Emission Tomography ◽  
Plaque Morphology ◽  
Non Invasive ◽  
Positron Emission ◽  
Artery Disease

Positron emission tomography (PET) with 18F-sodium fluoride (18F-NaF) has emerged as a promising non-invasive imaging modality to identify high-risk and ruptured atherosclerotic plaques. By visualizing microcalcification, 18F-NaF PET holds clinical promise in refining how we evaluate coronary artery disease, shifting our focus from assessing disease burden to atherosclerosis activity. In this review, we provide an overview of studies that have utilized 18F-NaF PET for imaging atherosclerosis. We discuss the associations between traditional coronary artery disease measures (risk factors) and 18F-NaF plaque activity. We also present the data on the histological validation as well as show how 18F-NaF uptake is associated with plaque morphology on intravascular and CT imaging. Finally, we discuss the technical challenges associated with 18F-NaF coronary PET highlighting recent advances in this area.

Sign in / Sign up

Export Citation Format

Share Document